Conventional Oncology Considers Pancreatic Cancer To Be Incurable- I don’t…
When a cancer patient is given a terminal diagnosis what is he/she supposed to do? When a cancer patient is given a therapy plan that, at best, is supposed to prolong his/her life for months not years, what is the patient to do?
Conventional oncology has little to offer a pancreatic cancer patient. While the study below talks about low-dose naltrexone (LDN) combined with alpha-lipoic acid (ALA) lengthening life and enhancing quality of life for pancreatic cancer patients, it is considered anecdotal evidence. Advanced pancreatic cancer patients may appreciate information about non-toxic therapies.
Alternative therapies listed in the articles linked and excerpted below have been shown to lengthen pancreatic overall survival while reducing side effects.
Make no mistake. Pancreatic cancer is an aggressive cancer. You will have to use every therapy tool at your disposal in order to manage your cancer.
I take Curcumin, vitamin C, alpha-lipoic acid and other supplements to remain in complete remission from my “incurable” cancer, multiple myeloma. Please read the articles below and consider supplementing with those nutriceuticals that you feel comfortable with.
For information about other complementary and integrative pancreatic cancer therapies such as Curcumin or omega 3 fatty acids, scroll down the page, post a question or a comment and I will reply ASAP.
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol.
“The treatment regimen includes the intravenous alpha-lipoic acid and low-dose naltrexone (ALA-N) protocol and a healthy lifestyle program.
The patient was told by a reputable university oncology center in October 2002 that there was little hope for his survival. Today, January 2006, however, he is back at work, free from symptoms, and without appreciable progression of his malignancy.
The integrative protocol described in this article may have the possibility of extending the life of a patient who would be customarily considered to be terminal.
The authors believe that life scientists will one day develop a cure for metastatic pancreatic cancer, perhaps via gene therapy or another biological platform. But until such protocols come to market, the ALA-N protocol should be studied and considered, given its lack of toxicity at levels reported. Several other patients are on this treatment protocol and appear to be doing well at this time.